Direkt zum Inhalt
Merck

S7656

Sigma-Aldrich

Anti-Staphylococcal Enterotoxin A antibody produced in rabbit

whole antiserum

Synonym(e):

Anti-Ent A

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

MDL-Nummer:
UNSPSC-Code:
12352203
NACRES:
NA.46

Biologische Quelle

rabbit

Qualitätsniveau

Konjugat

unconjugated

Antikörperform

whole antiserum

Antikörper-Produkttyp

primary antibodies

Klon

polyclonal

Enthält

15 mM sodium azide

Speziesreaktivität

Staphylococcus aureus

Methode(n)

dot blot: 1:20,000 using using purified Staphyloccal Enterotoxin A immobilized on nitrocellulose membranes (protein concentation: 50 ng/dot).
indirect ELISA: 1:20,000 using using Staphylococcal enterotoxin A

Versandbedingung

dry ice

Lagertemp.

−20°C

Posttranslationale Modifikation Target

unmodified

Verwandte Kategorien

Allgemeine Beschreibung

The antibody is positive against Staphylococcal enterotoxin A, negative versus Staphylococcal enterotoxin B, Cholera toxin, and Pseudomonas exotoxin A (protein concentration: 50-500 ng/dot). The antibody has not been tested for neutralization potency against active Staphylococcal enterotoxin A.

Immunogen

enterotoxin A from Staphylococcus aureus.

Anwendung

Anti-Staphylococcal Enterotoxin A antibody has been used in western blotting, and enterotoxin A detection by ELISA (enzyme-linked immunosorbent assay).
Anti-Staphylococcal Enterotoxin A antibody produced in rabbit was used as a control to SEA-conjugated MUSE11 antibody produced in xenografted SCID mice.

Biochem./physiol. Wirkung

Staphylococcal enterotoxin A (SEA) from Staphylococcal aureus is leading agent that causes of food poisoning. A concentration of as little as 0.5 mg/ml is sufficient to result in nausea, vomiting, diarrhea and cramps. It stimulates the cell proliferation of peripheral lymphocytes, induces the production of interferons and is important for gut immunity against S. aureus infections.

Haftungsausschluss

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Sie haben nicht das passende Produkt gefunden?  

Probieren Sie unser Produkt-Auswahlhilfe. aus.

Lagerklassenschlüssel

10 - Combustible liquids

WGK

WGK 1


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Molecular Screening of Staphylococcal Enterotoxin Type A Encoding Gene from MRS Clinical Isolates
Hussein H A, et al.
American Journal of Microbiological Research, 4(2), 68-72 (2016)
M Shinoda et al.
Cancer research, 58(13), 2838-2843 (1998-07-14)
To reinforce cytotoxic activity and the targeting ability of lymphokine-activated killer cells with a T-cell phenotype (T-LAK) for adoptive immunotherapy against human bile duct carcinoma (BDC), staphylococcal enterotoxin A (SEA) was conjugated chemically with MUSE11 monoclonal antibody (MUSE11 mAb), directed
N Sakurai et al.
Biochemical and biophysical research communications, 256(1), 223-230 (1999-03-06)
A SEA-antibody single chain Fv (SEA-scFv) fusion protein was produced by bacterial expression system in this study. SEA-scFv has both staphylococcal enterotoxin A (SEA) effects and antibody activity directed at the epithelial mucin core protein MUC1, a cancer associated antigen.
A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma
Takemura S I, et al.
Cancer Immunology, Immunotherapy, 51(1), 33-44 (2002)
Shin-ichi Takemura et al.
Cancer immunology, immunotherapy : CII, 51(1), 33-44 (2002-02-15)
In cancer immunotherapy research, many bispecific antibodies (BsAbs) have been developed for directing T cells toward tumor cells. Recent advances in genetic engineering have made it possible to prepare immunoglobulin fragments consisting of variable domains using bacterial expression systems. Therefore

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.